Promising Pathway Act
Latest action · Jun 18, 2020 Referred to the House Committee on Energy and Commerce.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 18, 2020
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Promising Pathway Act
This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable.
The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations.
During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis.
The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties.
A provisionally approved drug must be labeled as such.
If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded.
The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective.
Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.
Cosponsors 11
Members who signed on, in the order they did. Signatures ran from Jun 18, 2020 to Aug 21, 2020; 3 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-AR | Bruce Westerman | Original | Jun 18, 2020 |
| D-CA | Eric Swalwell | Original | Jun 18, 2020 |
| R-WI | Mike Gallagher | Original | Jun 18, 2020 |
| D-CA | Grace F. Napolitano | Jul 16, 2020 | |
| D-NJ | Jefferson Van Drew | Jul 16, 2020 | |
| R-NE | Don Bacon | Jul 23, 2020 | |
| R-PA | Brian K. Fitzpatrick | Jul 24, 2020 | |
| D-MN | Angie Craig | Jul 29, 2020 | |
| R-NY | Peter T. King | Jul 29, 2020 | |
| D-OH | Joyce Beatty | Aug 14, 2020 | |
| R-FL | Ted S. Yoho | Aug 21, 2020 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jun 18, 2020 |
Actions 2
Everything that happened, newest first.
- Jun 18, 2020Introduced in House
- Jun 18, 2020Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 166, no. 113, June 18, 2020, page H2407.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 3872 | Promising Pathway Act | Identical bill | Jun 3, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
- Short Title(s) as Introduced
- Promising Pathway Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Cardiovascular and respiratory health
- Civil actions and liability
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Emergency medical services and trauma care
- Employee benefits and pensions
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health care coverage and access
- Health information and medical records
- Immunology and vaccination
- Infectious and parasitic diseases
- Licensing and registrations
- Manufacturing
- Medical research
- Medical tests and diagnostic methods
- Prescription drugs
- Scientific communication
Text 1
Each version as it was printed, newest first.
- Jun 18, 2020Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.